Most Pharmacies assume that when a patient nomination moves It is because the patient made a conscious choice

Every pharmacy has experienced it.

A patient who has been with you for years — sometimes decades — suddenly stops receiving their prescriptions through your system.

In reality, that is only part of the picture, Across the sector, nomination losses typically fall into three distinct categories

Legitimate Patient Choice

Some patients actively choose to move pharmacies due to:

Location or convenience

Delivery preferences

Changes in routine or circumstances

These decisions are valid and should always be respected.

Renominate does not intervene in these cases.

Administrative or System-Driven Changes

Nominations are sometimes altered due to:

Misunderstandings during service interactions

Poorly explained consent requests

Administrative shortcuts

Digital processes that lack clear patient confirmation

In these cases, patients may not realise a change has taken place until something goes wrong with their prescription.

The Growing Issue: Unsolicited and Incentivised Targeting

An increasing concern across the sector is the rise of unsolicited patient targeting, where pharmacies actively contact patients who are not their existing customers.

This may include:

Cold calls, texts, or leaflets

Online advertising targeting specific patient groups

Promotional messaging framed as “help” or “convenience”

Incentives such as vouchers, rewards, or inducements

Renominating patients without consent in bulk using software automation

In some cases, patients are led to believe they are:

Updating their details

Confirming a service

Registering for delivery

Accessing a benefit

Without realising they have agreed to change their nominated pharmacy.

 Many patients later report:

They did not understand what they were agreeing to

They did not intend to leave their existing pharmacy

They were unaware a nomination change had even occurred

Why This Matters for Pharmacies

When nominations move without genuine patient intent:

Prescription volume is lost unfairly

Long-standing patient relationships are disrupted

Continuity of care is broken

Trust in the system is undermined

For pharmacies on the receiving end, the impact can be significant — yet difficult to challenge without a clear, compliant process.

 

 Where Renominate Fits In

Renominate exists to address only one part of this problem:

Identifying situations where a nomination changed without patient awareness

Giving patients clarity about what actually happened

Allowing patients to decide what they want to do next

We do not market.

We do not incentivise.

We do not interfere with legitimate choice.

We simply bring visibility and fairness back into a process that has become increasingly opaque.

As competition intensifies, the pharmacies that act professionally should not be the ones quietly losing patients they never meant to give up.

A better experience for your patients.

A stronger relationship for your pharmacy.

When a patient returns through RE-NOMINATE something important happens. They do not just regain their familiar pharmacy. They regain confidence. They regain clarity. They regain the certainty of a relationship they thought they had never left.

And your pharmacy regains a meaningful connection that should never have been lost in the first place.

Founder Partner Opportunity

We are currently welcoming a limited number of pharmacies to join as Founder Partners during the structured launch phase of the Renominate programme.

Founder Partners participate at the ground-floor stage of a carefully designed retention and digital credibility framework. During this phase, each partner receives direct oversight and measured implementation support to ensure long-term stability and success.

Founder Partner status includes:

• Direct founder-led implementation and strategic oversight
• Priority onboarding within the structured rollout phase
• Protected long-term commercial positioning within the programme
• Preferential access to all Renominate services and future enhancements
• Participation within a limited, quality-controlled launch cohort

Launch intake is intentionally restricted to ensure every Founder Partner receives the level of attention and structure the programme requires.